POL Scientific / Bladder / Volume 11 / Issue 2 / DOI: 10.14440/bladder.2024.0017
Submit to Bladder
Cite this article
25
Download
111
Citations
841
Views
Journal Browser
Volume | Year
Issue
Search
Forthcoming Issue
Current Issue
View All
News and Announcements
View All
RESEARCH ARTICLE

Therapeutic efficacy and short-term durability of trans-urethral amniotic bladder injections for the treatment of refractory COVID-associated cystitis

Jack A. Considine1 ,  Kyle O’Hollaren1 ,  John Knapp1 ,  Codrut Radoiu1 ,  Aron Liaw1,2 ,  Nivedita Dhar2,3*
Show Less
1 Department of Urology, Wayne State University School of Medicine, Detroit, Michigan, United States of America
2 John D. Dingell VA Medical Center, Detroit, Michigan, United States of America
3 Detroit Medical Center, Detroit, Michigan, United States of America
Bladder 2024 , 11(2), e21200010; https://doi.org/10.14440/bladder.2024.0017
Submitted: 17 July 2024 | Revised: 27 August 2024 | Accepted: 5 September 2024 | Published: 3 October 2024
© 2024 by the Author(s). This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution 4.0 International License ( https://creativecommons.org/licenses/by/4.0/ )
Download PDF
Cite
XML
HTML
Abstract

Introduction: COVID-19-associated cystitis (CAC) may arise following a COVID-19 infection and is characterized by the development of novel or worsening overactive bladder (OAB). CAC is possibly associated with bladder mucosal damage and the release of pro-inflammatory cytokines, resulting in inflammation and fibrosis of the bladder wall. Amniotic membrane (AM) has been shown to possess anti-inflammatory and anti-fibrotic properties and might potentially be beneficial for CAC. This study investigated the safety and efficacy of bladder injections of AM in CAC patients with resistant OAB symptoms. Methods: Five CAC patients, with an average age of 73 ± 1.0 years and a median disease duration of 2.4 years, received intra-detrusor injections of 100 mg micronized AM under general anesthesia and were followed for 20 weeks. Key urodynamic measures (involuntary detrusor contraction and maximum cystometric capacity) were determined to evaluate treatment response. Quality of life (QOL) was assessed using the OAB assessment tool, and safety was analyzed. Results: All five patients showed improved urodynamic bladder function and significantly improved QOL improvements. The improvement was evident from 4 weeks post-treatment and sustained until 12 weeks. Symptoms re-surged at 20 weeks. No safety concerns arose during the study. Conclusion: The observed improvements in symptom scores and bladder volume parameters highlighted the promise of AM bladder injections as a viable intervention for CAC patients with refractory OAB symptoms. Comprehensive studies are needed to validate its therapeutic potential, and treatment protocol refinement is warranted to address the observed reduction in efficacy over time.

Keywords
Amniotic bladder therapy
Bladder function
COVID-19
COVID-19-associated cystitis
Micronized amniotic membrane
Overactive bladder
Pro-inflammatory cytokines
Urodynamic study
Viral cystitis
Funding
None.
References
  1. Raveendran AV, Jayadevan R, Sashidharan S. Long COVID: An overview. Diabetes Metab Syndr. 2021;15(3):869-875. doi: 10.1016/j.dsx.2021.04.007

 

  1. Dhar N, Dhar S, Timar R, Lucas S, Lamb LE, Chancellor MB. De novo urinary symptoms associated with COVID-19: COVID-19-associated cystitis. J Clin Med Res. 2020;12(10):681-682. doi: 10.14740/jocmr4294

 

  1. Lamb LE, Dhar N, Timar R, Wills M, Dhar S, Chancellor MB. COVID-19 inflammation results in urine cytokine elevation and causes COVID-19 associated cystitis (CAC). Med Hypotheses. 2020;145:110375. doi: 10.1016/j.mehy.2020.110375

 

  1. Zou X, Chen K, Zou J, Han P, Hao J, Han Z. Single-cell RNA-seq data analysis on the receptor ACE2 expression reveals the potential risk of different human organs vulnerable to 2019- nCoV infection. Front Med. 2020;14(2):185-192. doi: 10.1007/s11684-020-0754-0

 

  1. Tseng SCG. HC-HA/PTX3 purified from amniotic membrane as novel regenerative matrix: Insight into relationship between inflammation and regeneration. Invest Ophthalmol Vis Sci. 2016;57(5):ORSFh1-ORSFh8. doi: 10.1167/iovs.15-17637

 

  1. Tighe S, Mead OG, Lee A, Tseng SCG. Basic science review of birth tissue uses in ophthalmology. Taiwan J Ophthalmol. 2020;10(1):3-12. doi: 10.4103/tjo.tjo_4_20

 

  1. Madan R, Radoiu C, Liaw A, Lucas S, Hamada A, Dhar N. Early three-month report of amniotic bladder therapy in patients with interstitial cystitis/bladder pain syndrome. Int Urol Nephrol. 2023;55(8):1937-1942. doi: 10.1007/s11255-023-03652-8

 

  1. Radoiu C, Jeberaeel J, Madan R, et al. A preliminary report assessing the feasibility and effectiveness of amniotic bladder therapy in patients with chronic radiation cystitis. Can J Urol. 2023;30(4):11607-11612.

 

  1. Wittenberg S, Madan R, Liaw A, Lucas S, Hamada A, Dhar N. Amniotic bladder therapy in patients with recalcitrant interstitial cystitis and bladder pain syndrome. Can Urol Assoc J. 2023;17(11):E402-E404. doi: 10.5489/cuaj.8441

 

  1. Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology in lower urinary tract function: Report from the standardisation sub-committee of the International Continence Society. Urology. 2003;61(1):37-49. doi: 10.1016/s0090-4295(02)02243-4

 

  1. Mumm JN, Osterman A, Ruzicka M, et al. Urinary frequency as a possibly overlooked symptom in COVID-19 patients: Does SARS-CoV-2 cause viral cystitis? Eur Urol. 2020;78(4):624-628. doi: 10.1016/j.eururo.2020.05.013

 

  1. Lamb LE, Timar R, Wills M, et al. Long COVID and COVID-19-associated cystitis (CAC). Int Urol Nephrol. 2022;54(1):17-21. doi: 10.1007/s11255-021-03030-2

 

  1. Grover S, Srivastava A, Lee R, Tewari AK, Te AE. Role of inflammation in bladder function and interstitial cystitis. Ther Adv Urol. 2011;3(1):19-33. doi: 10.1177/1756287211398255

 

  1. Fry CH, Vahabi B. The role of the mucosa in normal and abnormal bladder function. Basic Clin Pharmacol Toxicol. 2016;119 Suppl 3(Suppl 3):57-62. doi: 10.1111/bcpt.12626

 

  1. He H, Li W, Tseng DY, et al. Biochemical characterization and function of complexes formed by hyaluronan and the heavy chains of inter-alpha-inhibitor (HC*HA) purified from extracts of human amniotic membrane. J Biol Chem. 2009;284(30):20136-20146. doi: 10.1074/jbc.M109.021881

 

  1. He H, Zhang S, Tighe S, Son J, Tseng SCG. Immobilized heavy chain-hyaluronic acid polarizes lipopolysaccharide-activated macrophages toward M2 phenotype. J Biol Chem. 2013;288(36):25792-25803. doi: 10.1074/jbc.M113.479584

 

  1. Moretti L, Stalfort J, Barker TH, Abebayehu D. The interplay of fibroblasts, the extracellular matrix, and inflammation in scar formation. J Biol Chem. 2022;298(2):101530. doi: 10.1016/j.jbc.2021.101530

 

  1. Liu J, Sheha H, Fu Y, Liang L, Tseng SC. Update on amniotic membrane transplantation. Expert Rev Ophthalmol. 2010;5(5):645-661. doi: 10.1586/eop.10.63

 

  1. Burmeister D, Aboushwareb T, Tan J, Link K, Andersson KE, Christ G. Early stages of in situ bladder regeneration in a rodent model. Tissue Eng Part A. 2010;16(8):2541-2451. doi: 10.1089/ten.TEA.2009.0697

 

  1. Hastings JC, Van Winkle W, Barker E, Hines D, Nichols W. The effect of suture materials on healing wounds of the bladder. Surg Gynecol Obstet. 1975;140(6):933-937.

 

  1. McQuilling JP, Vines JB, Kimmerling KA, Mowry KC. Proteomic comparison of amnion and chorion and evaluation of the effects of processing on placental membranes. Wounds. 2017;29(6):E36-E40.

 

  1. Baskin LS, Sutherland RS, Thomson AA, et al. Growth factors in bladder wound healing. J Urol. 1997;157(6):2388-2395.

 

  1. Mangera A, Chapple CR, Kopp ZS, Plested M. The placebo effect in overactive bladder syndrome. Nat Rev Urol. 2011;8(9):495-503. doi: 10.1038/nrurol.2011.99

 

  1. Mostafaei H, Janisch F, Mori K, et al. Placebo response in patients with oral therapy for overactive bladder: A systematic review and meta-analysis. Eur Urol Focus. 2022;8(1):239-252. doi: 10.1016/j.euf.2021.02.005

 

  1. Dowson C, Sahai A, Watkins J, Dasgupta P, Khan MS. The safety and efficacy of botulinum toxin-A in the management of bladder oversensitivity: A randomised double-blind placebo-controlled trial. Int J Clin Pract. 2011;65(6):698-704. doi: 10.1111/j.1742-1241.2011.02663.x

 

  1. Brubaker L, Richter HE, Visco A, et al. Refractory idiopathic urge urinary incontinence and botulinum A injection. J Urol. 2008;180(1):217-222. doi: 10.1016/j.juro.2008.03.028

 

  1. Sievert KD, Chapple C, Herschorn S, et al. OnabotulinumtoxinA 100U provides significant improvements in overactive bladder symptoms in patients with urinary incontinence regardless of the number of anticholinergic therapies used or reason for inadequate management of overactive bladder. Int J Clin Pract. 2014;68(10):1246-1256. doi: 10.1111/ijcp.12443

 

  1. Cakir OO, Castiglione F, Tandogdu Z, et al. Management of penile cancer patients during the COVID-19 pandemic: An eUROGEN accelerated Delphi consensus study. Urol Oncol. 2021;39(3):197.e9.e17. doi: 10.1016/j.urolonc.2020.12.005

 

  1. Mancini M, Randazzo G, Piazza G, Dal Moro F. Arterial thrombotic complications in COVID-19: A case of renal infarction. Biomedicines. 2022;10(10):2354. doi: 10.3390/biomedicines10102354

 

  1. Wittenberg S, Vercnocke J, Chancellor M, et al. Prolonged impacts of COVID-19-associated cystitis: A study on long-term consequences. World J Clin Cases. 2023;11(33):7987-7993. doi: 10.12998/wjcc.v11.i33.7987

 

  1. Morlacco A, Mancini M, Soligo M, et al. Relevance of the endoscopic evaluation in the diagnosis of bladder pain syndrome/interstitial cystitis. Urology. 2020;144:106-110. doi: 10.1016/j.urology.2020.06.032

 

  1. Lutchka J, Vercnocke J, Fisher E, et al. Treatment of chronic post-radiation cystitis with trans-urethral amniotic bladder therapy appears durable at 9 months: A clinical study. Urologia. 2024;91(3):623-627. doi: 10.1177/03915603241248014

 

  1. Saponaro M, Giacomini I, Morandin G, et al. Serenoa repens and Urtica dioica fixed combination: In-vitro validation of a therapy for benign prostatic hyperplasia (BPH). Int J Mol Sci. 2020;21(23):9178. doi: 10.3390/ijms21239178
Conflict of interest
The authors declare no conflicts of interest. The product was not donated by the Company.
Share
Back to top
Bladder, Electronic ISSN: 2327-2120 Print ISSN: TBA, Published by POL Scientific
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here
Accept